Bioject and Chronimed Announce Supply Agreement

Bioject Medical Technologies, a developer of needle-free drug delivery systems, has entered into a supply agreement with Chronimed, a specialty pharmacy that distributes pharmaceuticals and provides specialized patient management services for people with HIV/AIDS.

The agreement calls for the sale of Biojector 2000 (B-2000) needle-free systems and related accessories to Chronimed for distribution to eligible patients who are using FUZEON, an AIDS drug developed by Trimeris in collaboration with Roche. Financial terms of the agreement between Bioject and Chronimed were not disclosed.

Early data found that patients who were administered a single dose of FUZEON with Bioject's B-2000 achieved equivalent drug levels in the blood compared to those who were administered FUZEON with the standard needle and syringe. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath.